SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-011681
Filing Date
2024-01-22
Accepted
2024-01-22 07:34:29
Documents
17
Period of Report
2024-01-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d699582d8k.htm   iXBRL 8-K 33650
2 EX-4.1 d699582dex41.htm EX-4.1 70964
3 EX-10.1 d699582dex101.htm EX-10.1 305900
4 EX-10.2 d699582dex102.htm EX-10.2 159679
5 EX-99.1 d699582dex991.htm EX-99.1 11728
9 GRAPHIC g699582g0119134757173.jpg GRAPHIC 4369
  Complete submission text file 0001193125-24-011681.txt   837587

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA dnth-20240122.xsd EX-101.SCH 2859
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE dnth-20240122_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dnth-20240122_pre.xml EX-101.PRE 11267
11 EXTRACTED XBRL INSTANCE DOCUMENT d699582d8k_htm.xml XML 3443
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 24547087
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)